News Orphazyme A/S

Equities

Market Closed - Nasdaq Copenhagen Other stock markets 07:04:32 2024-04-22 am EDT			5-day change	1st Jan Change
1,005 ^DKK	-4.01%		-4.27%	-24.44%

Mar. 27	Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 04	FDA Extends Review of Zevra's Arimoclomol by Three Months	DJ

STALICLA Appoints Dr. Thomas Blaettler, MD	Apr. 12	AQ
Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
FDA Extends Review of Zevra's Arimoclomol by Three Months	Mar. 04	DJ
BioStock: Comments from Orphazyme on the investment in CombiGene	Mar. 04	AQ
The Danish company Orphazyme has acquired 10% of the shares in CombiGene	Feb. 21	AQ
Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI).	Feb. 20	CI
Zevra Therapeutics Refiles Arimoclomol Application With FDA	Dec. 27	DJ
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	23-10-10	AQ
Niemann-Pick-Disease Pipeline, FDA Approvals, Clinical Trials, and Emerging Drugs 2023 (Updated)	23-09-28	AQ
Orphazyme A/S Provides Earnings Guidance for the Full Year 2023	23-09-12	CI
Orphazyme A/S Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-12	CI
Change in management	23-05-30	GL
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CEO	23-05-30	CI
Orphazyme A/S Announces Anders Fink Vadsholt to Step Down as CFO	23-05-30	CI
Orphazyme A/S Provides Earnings Guidance for the Full-Year 2023	23-05-30	CI
Major shareholder announcement	23-05-19	GL
Major shareholder announcement	23-05-17	GL
Resolutions passed at the Annual General Meeting	23-05-17	GL
Changes to the Board of Directors	23-05-17	AQ
Changes to the Board of Directors	23-05-17	GL

No results for this search